Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia
Status:
Not yet recruiting
Trial end date:
2030-12-31
Target enrollment:
Participant gender:
Summary
- Clinical and genetic factors consistent with High risk : Induction → Consolidation
1. BM MRD < 0.01% : IM #1 → DI #1 → IM #2 → Maintenance
2. BM MRD ≥ 0.01% : IM #1 → DI #1 → IM #2 → DI #2 → Maintenance
3. BM MRD ≥ 0.01% after Consolidation
1. T cell ALL : Change to very high risk regimen
2. Pre-B ALL : IM #1 → Intensification
1. BM MRD < 0.01% after IM #1 : DI #1 → IM #2 → DI #2 → Maintenance
2. BM MRD ≥ 0.01% after IM #1 : Change to Very high risk regimen
- Difference in the number of 'interim maintenance(IM)' and
'delayed intensification(DI)' is important for chemotherapies
based on MRD.